Press Room

2nd Annual Pharmaceutical Portfolio Strategy & Management Conference

Start
Monday, May 13, 2019 - 00:00
End
Tuesday, May 14, 2019 - 00:00
Location: Philadelphia, United States

Leading portfolio executives are sharing perspectives on risk measurement, data integrity and governance, and maximizing R&D budget for new discoveries. 

Hovione is present at the 2nd Annual Pharmaceutical Portfolio Strategy & Management Conference in Philadelphia with a participation in a panel discussion.

 

HOVIONE PRESENTATION

Panel Title: Developing Agility in the Fast-paced Pharmaceutical Industry

Speaker: Steven Krivicich, Program & Portfolio Director at Hovione

Topics in discussion

  • Perspectives on current industry challenges
  • Maximizing internal capability for adjustment
  • Applying insights to move forward as an industry

 

If you are attending this conference and would like to chat with us about your projects, schedule a meeting with us. Our colleagues will be pleased to meet you.

 

Schedule a meeting button | Hovione

 

 

 

 

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025